Get the Stockscreener App
14.55
0.00%
0.00
Pre-market:
15.63
1.08
+7.42%
Eikon Therapeutics Inc stock is traded at $14.55, with a volume of 436.09K.
It is up +0.00% in the last 24 hours and up +0.00% over the past month.
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates.
See More
Previous Close:
$14.55
Open:
$15.87
24h Volume:
436.09K
Relative Volume:
66.00
Market Cap:
$785.47M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$14.10
$15.87
1-Week Range:
$14.10
$15.87
52-Week Range:
$14.10
$15.87
Eikon Therapeutics Inc Stock (EIKN) Company Profile
Compare EIKN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EIKN
Eikon Therapeutics Inc
|
14.55 | 782.77M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.87 | 121.26B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.28 | 83.04B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
828.24 | 50.22B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.00 | 43.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
348.85 | 39.16B | 4.98B | 69.60M | 525.67M | 0.5198 |
Eikon Therapeutics Inc Stock (EIKN) Latest News
Wall Street Braces For IPO Boom: Goldman Says 2026 Listings Could Hit $160 Billion As Tech, AI Lead - Benzinga
Eikon Therapeutics completes IPO and updates governance documents - The Globe and Mail
Eikon, Agomab raise $350M total in IPOs, sink in aftermarket: Public Equity Report - biocentury.com
Finance Watch: Four IPOs In One Week - Citeline News & Insights
Eikon Therapeutics, Late-Stage Clinical Oncology Drug Developer, Files for Nasdaq IPO - TradingView
Eikon Therapeutics valued at $860 million in Nasdaq debut - marketscreener.com
Eikon Therapeutics Continues the IPO Parade, Raising $381M for Cancer Drug Clinical Trials - MedCity News
Covington, Davis Polk Lead Eikon's Upsized $381M IPO - Law360
Eikon Therapeutics Shares Fall in Nasdaq Debut - marketscreener.com
Merck veteran Perlmutter-led Eikon Therapeutics valued at $860 million in Nasdaq debut - Yahoo Finance
Eikon IPO grows to biggest for biotech since 2024, raising nearly $400 million before stock falls in debut - The Business Journals
Eikon Therapeutics Opens At $17.05, IPO Priced At $18 By Investing.com - Investing.com Canada
Eikon’s $381M raise represents largest biopharma IPO in two years - BioWorld MedTech
Eikon Therapeutics, Inc. Rings the Opening Bell - Nasdaq
Perlmutter-backed Eikon Therapeutics raises $381.2 million in IPO - 1470 & 100.3 WMBD
Eikon Therapeutics raises $381M in IPO - Axios
Eikon Therapeutics nets a $381M IPO amid burst of biotech offerings - BioPharma Dive
Eikon Therapeutics prices upsized IPO at $18 per share By Investing.com - Investing.com Nigeria
Merck Veteran-Led Eikon Therapeutics Raises $381 Million in IPO - bloomberg.com
Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering - Chartmill
Preview: Eikon Therapeutics, Inc Set To IPO Tomorrow - Benzinga
Eikon Therapeutics IPO: Pipeline, Technology Platform, Key Collaborations & Investment Highlights for 2026 - Minichart
Eikon aims high for NASDAQ listing: Public Equity Report - BioCentury
IPO Rating: Eikon Therapeutics, Inc. - Smartkarma
Eikon Therapeutics seeks up to $317M raise in Nasdaq IPO - BioWorld MedTech
Market Chatter: Merck Expected to Take $30 Million Stake in Eikon Therapeutics' IPO - 富途牛牛
Merck veteran-led Eikon seeks $908M valuation in US IPO - MSN
Merck (MRK) Invests in Eikon Therapeutics' IPO - GuruFocus
Merck to Acquire $30M Stake in Eikon Therapeutics - intellectia.ai
Merck veteran Perlmutter-led Eikon Therapeutics eyes $908 million valuation in IPO - MSN
Merck veteran Perlmutter-led Eikon ?Therapeutics eyes $908 million valuation in IPO - marketscreener.com
Eikon Therapeutics targets $317M raise in IPO - Axios
Eikon Therapeutics Eyes $908M Valuation in U.S. IPO Under Roger Perlmutter's Leadership - StockInvest.us
Eikon Therapeutics Launches IPO For Ambitious Oncology Pipeline Development (Pending:EIKN) - Seeking Alpha
IPOs, whale-sized fundings and an animal testing debate ahead of biotech's big JPM conference - The Business Journals
Eikon, a high-profile startup led by Merck vets, seeks an IPO - BioPharma Dive
Phase 2 biotech developing in-licensed therapies for immuno-responsive cancers. - renaissancecapital.com
Eikon Therapeutics Announces the Election of David W. Meline to its Board of Directors - Business Wire
Eikon Therapeutics to Present New Phase 2 Data on EIK1001 in First-Line Non-Small Cell Lung Cancer at ESMO 2025 - Business Wire
Eikon Therapeutics to Share Clinical Data and Program Updates at the 2025 ASCO Annual Meeting - Business Wire
Bay Area biotech company cuts 55 jobs, blames Trump-era funding reductions - San Francisco Chronicle
Well-funded biotech company lays off 55 in Bay Area, blames Trump admin - SFGATE
Eikon Therapeutics just raised $351 million — now it's cutting jobs thanks to Trump rollbacks - The Business Journals
In Vivo’s 2025 Rising Leaders - Citeline News & Insights
Eikon Therapeutics describes new WRN inhibitors - BioWorld MedTech
Biotech Startup Eikon Therapeutics Locks Up Massive $351M Series D - Crunchbase News
Eikon strikes it rich again, securing $351M to fund cancer trials globally - Medical Marketing and Media
Eikon Therapeutics Announces Nature Methods Publication Highlighting its Pioneering Oblique Line Scan Technology - BioSpace
Eikon Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
Eikon Therapeutics Appoints COO: People in the News: 11/27/24 | Business | Nov 2024 - Photonics Spectra
Eikon Therapeutics Announces Appointment of Michael Klobuchar as Chief Operating Officer - Business Wire
Eikon Therapeutics Inc Stock (EIKN) Financials Data
There is no financial data for Eikon Therapeutics Inc (EIKN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.10%
7.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):